Quantcast
Search Daily Dose & Film Annex
Loading

BIO SmartBrief

Daily Dose Newsletter

Wednesday
Apr252012

Soligenix ($SNGX): Announces further progress with ThermoVax 

Soligenix announced that progress has been based on additional characterization of the stability of prototype vaccines that have been kept at elevated temperatures in excess of three months.

  • Prior results have indicated that the company's aluminum-adjuvanted ricin toxin vaccine, known as RiVax, retained effectiveness and potency while stored at 40 degrees Celsius for one month when combined with the ThermoVax technology.
  • Confirmatory results have now extended these initial observations to more than three months when the vaccine is kept at 40 degrees Celsius. In contrast, liquid RiVax vaccine when stored at 40 degrees Celsius rapidly degraded and no longer maintained its effectiveness.

PrintView Printer Friendly Version

EmailEmail Article to Friend

References (1)

References allow you to track sources for this article, as well as articles that were written in response to this article.
  • Response
    Superb Webpage, Preserve the useful job. With thanks.

Reader Comments

There are no comments for this journal entry. To create a new comment, use the form below.

PostPost a New Comment

Enter your information below to add a new comment.

My response is on my own website »
Author Email (optional):
Author URL (optional):
Post:
 
Some HTML allowed: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <code> <em> <i> <strike> <strong>
« Human Genome ($HGSI) RBC says current GSK bid for Human Genome undervalues sum of parts over long-run ($14.64) | Main | Coronado Biosciences receives recommendation to continue Falk phase 2 trial of TSO in Crohn's disease »